Patents Issued in December 30, 2010
-
Publication number: 20100330116Abstract: The present invention relates to live attenuated Salmonella cultures for use as vaccines. The Salmonella cultures of the present invention have a substantially reduced capacity to grow and replicate in the presence of bile. The reduced capacity for growth is due to a metabolic-drift mutation induced by exposure to a combination of nalidixic acid and rifampicin for a time and under conditions sufficient to induce the mutation.Type: ApplicationFiled: April 28, 2010Publication date: December 30, 2010Applicant: The University of QueenslandInventor: Tetsuo Mizuno
-
Publication number: 20100330117Abstract: The present invention provides a composition and method for treating diseases associated with demyelination of the nerves, such as ALS, RA, Tremors/Parkinson's Disease, and MS, Alzheimer's disease, ALS, Guillain-Barre syndrome, atherosclerosis, schizophrenia, Tremors/Parkinsons's disease, senile dementia, Muscular Dystrophy, Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder, Complex Regional Pain Syndrome, Diabetes, Neuropathic Pain, Spider Arthritis West Nile Virus, Fibromyalgia, Shingles, Gout, Migraine Headaches, Post Polio Syndrome, Central Virus Deafness, Asthma, Chronic Pain Of Unknown Origin and Hepatitis C and for treating non-viral based cancers. By administering measured doses of an immunity-provoking agent and a bacterial antigen activator, patients suffering from ALS, RA, MS, Tremors/Parkinson's Disease, and prostate cancer and others realized immediate beneficial results with no side effects.Type: ApplicationFiled: April 13, 2010Publication date: December 30, 2010Applicant: SALUBRIOUS PHARMACEUTICAL, LLCInventor: George Nelson
-
Publication number: 20100330118Abstract: Polypeptides, polynucleotides, reassortant viruses, immunogenic compositions and vaccines comprising influenza hemagglutinin and neuraminidase variants and method using thereof are provided.Type: ApplicationFiled: February 3, 2010Publication date: December 30, 2010Applicants: MEDIMMUNE, LLC, The Government of the United States of America, National Institutes of HealthInventors: Hong JIN, Xing CHENG, Kanta SUBBARAO
-
Publication number: 20100330119Abstract: A Chromatography medium having the properties of high virus adsorption and high fluidity, and a method for producing a virus vaccine using these are provided. The Chromatography medium is formed by binding a sulfated polysaccharide to porous particles having an exclusion limit molecular weight of 6000 Da or less when pure water is used as mobile phase and standard polyethylene glycol is used and an average particle size in the range of 30-200 ?m.Type: ApplicationFiled: June 24, 2010Publication date: December 30, 2010Applicant: CHISSO CORPORATIONInventors: YUKA YAMAMOTO, YUICHI YAMAMOTO, YASUTO UMEDA, SHIGEYUKI AOYAMA, YOSHIHIRO MATSUMOTO
-
Publication number: 20100330120Abstract: The invention provides self replicating infectious recombinant paramyxoviruses where the P and C genes are separated rated. The recombinant paramyxoviruses preferably have one or more attenuating mutations and/or at least one temperature sensitive mutation and one non-temperature sensitive mutation. In some embodiments, the recombinant paramyxovirus has a separate variant polynucleotide encoding a C protein and a separate monocistronic polynucleotide encoding a P protein. Also provided are compositions and methods for using the recombinant paramyxoviruses as described herein.Type: ApplicationFiled: May 8, 2008Publication date: December 30, 2010Inventors: Peter L. Collins, Brian R. Murphy, Mario H. Skiadopoulos, Emmalene J. Bartlett, Alexander C. Schmidt, Ann-Marie M. Cruz
-
Publication number: 20100330121Abstract: Isolated nucleic acid molecules are disclosed, comprising an alphavirus nonstructural protein gene which, when operably incorporated into a recombinant alphavirus particle, eukaryotic layered vector initiation system, or RNA vector replicon, has a reduced level of vector-specific RNA synthesis, as compared to wild-type, and the same or greater level of proteins encoded by RNA transcribed from the viral junction region promoter, as compared to a wild-type recombinant alphavirus particle. Also disclosed are RNA vector replicons, alphavirus vector constructs, and eukaryotic layered vector initiation systems which contain the above-identified nucleic acid molecules.Type: ApplicationFiled: July 28, 2010Publication date: December 30, 2010Applicants: NOVARTIS VACCINES AND DIAGNOSTICS, INC., WASHINGTON UNIVERSITYInventors: Thomas W. Dubensky, JR., John M. Polo, Barbara A. Belli, Sergey A. Dryga, Sondra Schlessinger, Ilya Frolov
-
Publication number: 20100330122Abstract: The present invention discloses novel Varicella Zoster Virus (VZV) virus-like particles (VLPs) comprising glycoprotein E of VZV. The invention also discloses vaccine formulations of the VZV-VLPs and methods of inducing an immune response in subjects.Type: ApplicationFiled: July 21, 2008Publication date: December 30, 2010Inventors: Gale Smith, Peter Pushko
-
Publication number: 20100330123Abstract: This invention relates to botulinum toxin formulations that are stabilized without the use of any proteinaceous excipients. The invention also relates to methods of preparing and using such botulinum toxin formulations.Type: ApplicationFiled: June 25, 2010Publication date: December 30, 2010Applicant: Revance Therapeutics, Inc.Inventors: Stewart A. Thompson, Curtis L. Ruegg, Jacob M. Waugh
-
Publication number: 20100330124Abstract: The present invention provides a novel immunogenic composition, vaccine and methods for making and using the immunogenic composition and vaccine. The immunogenic composition is capable of providing an immune response and/or a protective immunity into subjects, preferably mammals, against microorganism-associated disease. The immunogenic composition includes one or more extracellular proteins isolated from a microorganism capable of providing an immune response and/or a protective immunity into subjects against microorganism-associated disease. The isolated extracellular proteins range in molecular weight from about 10,000 Da to about 220,000 Da. Suitable microorganisms may include members of the genus Salmonella, Listeria, Pseudomonas, Staphylococcus, and Vibrio. Kits are also encompassed for detection, diagnosis and prevention of microorganism-associated disease.Type: ApplicationFiled: June 23, 2010Publication date: December 30, 2010Inventor: Richard E. COWART
-
Publication number: 20100330125Abstract: The application relates to Clostridium difficile cell surface polysaccharides, compositions comprising Clostridium difficile cell surface polysaccharides, and includes kits, methods and uses thereof.Type: ApplicationFiled: September 11, 2008Publication date: December 30, 2010Applicant: UNIVERSITY OF GUELPHInventors: Mario Artur Monteiro, Jeyabarathy Ganeshapillai
-
Publication number: 20100330126Abstract: The present invention relates to an attenuated Plasmodium parasite having a genome comprising a non-reversible knockout of the PyPNP gene, a vaccine derived therefrom, and related methods and uses.Type: ApplicationFiled: February 25, 2010Publication date: December 30, 2010Inventors: Kami Kim, Li-Min Ting
-
Publication number: 20100330127Abstract: A soluble aggregate of allergen proteins, prepared by heating multiple allergen proteins and aggregating the allergen proteins and thus enclosing the antigen structures causing allergic reactions therein.Type: ApplicationFiled: May 7, 2010Publication date: December 30, 2010Applicants: WAKO FILTER TECHNOLOGY CO., LTD., PROTEC CO., LTD.Inventors: Akira Saito, Akio Kato
-
Publication number: 20100330128Abstract: A method of improving immune-function in mammals using selected 3-HPA producing lactic acid bacteria with a medium chain triglyceride (MCT) oil.Type: ApplicationFiled: September 8, 2010Publication date: December 30, 2010Inventors: Ho-Jin Kang, Bamonn Connolly
-
Publication number: 20100330129Abstract: The object of the invention consists of pharmaceutical formulations containing rifaximin in the shape of microgranules made gastroresistant by an insoluble polymer at pH values between 1.5 and 4.0 and soluble at pH values between 5.0 and 7.5, by their preparation and by their use in the manufacture of medicinal preparations useful in the treatment of inflammatory bowel diseases (IBD) and mainly Crohn's disease.Type: ApplicationFiled: January 28, 2010Publication date: December 30, 2010Applicant: ALFA WASSERMANN S.P.A.Inventors: Giuseppe Claudio Viscomi, Ernesto Palazzini, Villiam Zamboni, Maria Rosaria Pantaleo
-
Publication number: 20100330130Abstract: Provided herein are impurities of imatinib, N-(2-Methyl-5-methylamino-phenyl)-N-(4-pyridin-3-yl-pyrimidin-2-yl)-formamide (formamide impurity) and 4-[4-(Imidazole-1-carbonyl)-piperazin-1-ylmethyl]-N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-benzamide (carbonylimidazole impurity), and processes for the preparation and isolation thereof. Provided further herein is a highly pure imatinib or a pharmaceutically acceptable salt thereof substantially free of formamide and carbonylimidazole impurities, processes for the preparation thereof, and pharmaceutical compositions comprising highly pure imatinib or a pharmaceutically acceptable salt thereof substantially free of impurities. Disclosed also herein is a process for preparing substantially pure ?-form of imatinib mesylate.Type: ApplicationFiled: May 18, 2010Publication date: December 30, 2010Applicant: ACTAVIS GROUP PTC EHFInventors: Mayur Devjibhai KHUNT, Nilesh Sudhir PATIL, Haushabhau Shivaji PAGIRE, Nitin Sharadchandra PRADHAN
-
Publication number: 20100330131Abstract: Minocycline oral dosage forms containing a controlled release carrier are useful for the treatment of acne.Type: ApplicationFiled: September 3, 2010Publication date: December 30, 2010Applicant: MEDICIS PHARMACEUTICAL CORPORATIONInventors: Mitchell Wortzman, R. Todd Plott, Kuljit Bhatia, Bhiku Patel
-
Publication number: 20100330132Abstract: Composite particles formed of core particles and a silicone elastomer adhered to surfaces of the core particles.Type: ApplicationFiled: June 24, 2009Publication date: December 30, 2010Applicant: Shin-Etsu Chemical Co., Ltd.Inventors: Yoshinori INOKUCHI, Ryuichi INABA
-
Publication number: 20100330133Abstract: Extracts of at least one, and preferably a mixture of, encapsulated mixed plant carbohydrates (polysaccharides) are applied topically to the skin to mitigate the appearance of wrinkled skin and to improve the overall complexion of the skin. The mixed plant extracts are preferentially applied in a dehydrated state, with a preferred source for the polysaccharides being cacti. The application vehicle is preferentially an anhydrous product, which allows slight penetration of smaller fractions of the dehydrated mixed cactus carbohydrate into the stratum corneum. Upon entering the stratum corneum the cactus carbohydrates begin to hydrate and swell resulting in a plumping effect, with the overall appearance of lines and wrinkles diminishing.Type: ApplicationFiled: June 25, 2009Publication date: December 30, 2010Inventor: RICHARD A. PRESTI
-
Publication number: 20100330134Abstract: A depilatory composition comprising glucose syrup and a viscosity modifier comprising dextrose powder and/or crystals.Type: ApplicationFiled: February 19, 2008Publication date: December 30, 2010Applicant: Reckitt Benckiser (UK) LimitedInventors: Paul Ellis, Tracey Caldwell
-
Publication number: 20100330135Abstract: A cosmetic composition contains: a carotenoid (A), a collagen (B) having an average molecular weight of 40,000 or more, and a collagen peptide (C) having a weight average molecular weight of from 200 to 5,000.Type: ApplicationFiled: July 1, 2008Publication date: December 30, 2010Applicant: FUJIFILM CorporationInventors: Tomoko Tashiro, Toshiaki Kubo, Tatsuo Kawabuchi, Yukio Sudo
-
Publication number: 20100330136Abstract: This invention relates to a use of a composition for protecting oral cavity and teeth containing ethyl-N?-lauroyl-L-arginate HCl (LAE), a corresponding composition and a corresponding method for protecting teeth. Because of nearly epidemic incidence of dental erosion, there is a continuing need for improved products that provide protection against dental erosion. Hence, it is an object of the present invention to protect teeth against dental erosion. Surprisingly, it has been found that ethyl-N?-lauroyl-L-arginate HCl (LAE) and its salts attach to teeth and provide protection of teeth from erosion especially caused by the action of acid in food products and drinks such as chewing gum and lozenges compositions. Special advantages of this invention are: (a) sustained coating of the teeth by LAE and its homologues; (b) the coating agent provides a source of neutralizing plaque acids by providing sustained base formation.Type: ApplicationFiled: February 11, 2009Publication date: December 30, 2010Inventor: Xavier Rocabayera Bonvila
-
Publication number: 20100330137Abstract: The present invention relates to a pharmaceutical or dietary composition containing Mangosteen (Garcinia Mangostana pericarp) and being characterized by high bioavailability. A process for the manufacture of this composition is a further object of the present invention. In particular, the present invention relates to a composition containing Mangosteen extract and oligosaccharides in an amount ranging from 5 to 50 w/w % with respect to the Mangosteen extract or a fermented Mangosteen product and to a process for obtaining thereof.Type: ApplicationFiled: March 10, 2008Publication date: December 30, 2010Inventor: Mauro Mantovani
-
Publication number: 20100330138Abstract: Biostable, multipurpose, microbicidal intravaginal devices in the form of rings, ringed-meshes, sponges, or diaphragms for use by women and condoms for use by male partners are provided, wherein each of the devices contains a drug effective in treating a particular vaginal infection, while further exhibiting at least one additional function selected from the group dealing with non-hormonal contraception, management of sexually transmitted diseases, viral infections, and retroviral infections as well as the treatment of cervical cancer.Type: ApplicationFiled: May 11, 2009Publication date: December 30, 2010Inventors: Shalaby W. Shalaby, Georgios T. Hilas
-
Publication number: 20100330139Abstract: The present invention relates to substrate loaded with a cleaning composition containing C8-C10 alkylpolyglucosides which have low filming and streaking when combined with C2-C4 alcohols. The cleaning composition may also comprises a C2 to C4 alcohol, a water-soluble organic acid and a glycerol. The cleaning composition may optionally comprise dyes, builders, fatty acids, fragrances, colorants, glycerol, anti-foaming agents, and preservatives. The nonwoven substrate material comprises unmodified and modified natural fibers. The nonwoven substrate material is at least 90% biodegradable under compost conditions. The substrate loaded with the cleaning composition is also at least 90% biodegradable under compost conditions.Type: ApplicationFiled: March 3, 2009Publication date: December 30, 2010Inventors: Laura Shimmin, Sonia H. Burciaga, Bernard Hill, Ryan K. Hood, Thomas W. Kaaret, Andrew Kilkenny, Stephen Bradford Kong
-
Publication number: 20100330140Abstract: A facial mask for use in decreasing the transmission of one or more than one human pathogen to and from a human wearer of the facial mask, the facial mask comprising a facepiece; where the facepiece comprises three or more than three layers; where one or more than one of the three or more than three layers comprises a fabric comprising one or more than one binding substance comprising one or more than one human pathogen binding group for chemically attaching the human pathogen to the binding substance; where the fabric further comprises one or more than one type of multivalent metallic ion or metallic salt; and where one or more than one of the three or more than three layers comprises a heat-moldable fabric.Type: ApplicationFiled: June 25, 2008Publication date: December 30, 2010Applicant: FILLIGENT LIMITEDInventors: Neal G. Stewart, Lok Yuen Lo, Francis Chi Nan Lau, Dacey J. Ryan, Reid W. von Borstel
-
Publication number: 20100330141Abstract: A product for absorption purposes comprises a water insoluble support matrix substituted with a hydrophobic entity and a positively charged entity. The hydrophobic entity comprises di-alkyl carbamoyl chloride (DACC) and the positively charged entity comprises polyethyleneimine (PEI). The product is capable of removing microorganisms, including viruses, from air and liquid. Methods for manufacturing the product and uses and applications of the product are also presented.Type: ApplicationFiled: September 13, 2010Publication date: December 30, 2010Inventors: Torkel WADSTRÖM, Asa LJUNGH, Marie-Christine HJERTÉN, Nils-Gunnar LLBÄCK, Stellan HJERTÉN
-
Publication number: 20100330142Abstract: The invention relates to a composition comprising a) silver and/or one or more silver compound and b) one or more biocidal active ingredients of the isothiazoline.Type: ApplicationFiled: February 20, 2008Publication date: December 30, 2010Applicant: CLARIANT FINANCE (BVI) LIMITEDInventors: Uwe Falk, Michael Marcus Walter, Joerg Grohmann
-
Publication number: 20100330143Abstract: Described herein are composites produced by reacting a first thiolated macromolecule with at least one compound having at least one thiol-reactive electrophilic functional group. The methods described herein permit the cross-linking of a variety of different thiolated macromolecules with one another. The composites described herein have a variety of biomedical and pharmaceutical applications, which are also described herein.Type: ApplicationFiled: April 21, 2010Publication date: December 30, 2010Applicant: UNIVERSITY OF UTAH RESEARCH FOUNDATIONInventors: Glenn D. Prestwich, Aleksander Skardal, Jianxing Zhang
-
Publication number: 20100330144Abstract: Disclosed herein are three-dimensional porous tubular scaffolds for cardiovascular, periphery vascular, nerve conduit, intestines, bile conduct, urinary tract, and bone repair/reconstruction applications, and methods and apparatus for making the same.Type: ApplicationFiled: June 25, 2010Publication date: December 30, 2010Applicant: 3D BIOTEK, LLCInventors: Qing Liu, Zongsen Wang, Wing K. Lau
-
Publication number: 20100330145Abstract: A biobeneficial coating composition for coating an implantable device, such as a drug eluting stent, a method of coating the device with the composition, and an implantable device coated with the composition are provided.Type: ApplicationFiled: September 2, 2010Publication date: December 30, 2010Inventor: Stephen D. PACETTI
-
Publication number: 20100330146Abstract: An appliance for the delivery of at least one bioactive agent to the eye has at least one diffusion attenuator within a hydrophilic or silicone-hydrogel contact lens. The bioactive agent can be a drug or a nutraceutical. The diffusion attenuator can be a plurality of solid particles or phase separated liquid aggregates within at least one continuous phase of the lens where the diffusion attenuators promote a tortuous path for the diffusion of the bioactive agent to mediate the rate by which the bioactive agent diffuses from the contact lens. The diffusion attenuator can be homogeneously dispersed throughout at least one continuous phase of the lens to modify the diffusivity of the bioactive agent through that phase. The diffusion attenuator can have little or no affinity for the bioactive agent or can be miscible with the bioactive agent. The diffusion attenuator can be incorporated while forming the contact lens by polymerization of a monomer mixture containing the diffusion attenuator.Type: ApplicationFiled: July 22, 2010Publication date: December 30, 2010Applicant: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION INC.Inventors: ANUJ CHAUHAN, JINAH KIM
-
Publication number: 20100330147Abstract: The current invention is directed to compositions comprising a plurality of particles including nanoshells or a medical device with a coating including nanoshells allowing for triggered drug release. Methods of treatment with such compositions are also included.Type: ApplicationFiled: June 26, 2009Publication date: December 30, 2010Applicant: Abbott Cardiovascular Systems Inc.Inventors: Syed F. A. Hossainy, John J. Stankus, Dariush Davalian
-
Publication number: 20100330148Abstract: Described herein are methods of inhibiting IMPDH type 1, and treating or preventing a disease or disorder (or symptoms thereof) associated with IMPDH type 1, wherein an IMPDH type 1 inhibitor compound is administered to a subject.Type: ApplicationFiled: March 20, 2007Publication date: December 30, 2010Applicant: The Johns Hopkins UniversityInventors: Jun O. Liu, Curtis Robert Chong, David J. Sullivan
-
Publication number: 20100330149Abstract: A drug dosage form is provided in the form of a solid tablet which is greater than 50% by weight the local anesthetic agent. The local anesthetic agent may be selected from the group consisting of an aminoamide, an aminoester, and a combination thereof. The drug tablet may be in the form of a mini-tablet which is greater than 70 wt % drug, with the balance being excipient. For example, the anesethetic agent may include lidocaine, in a salt or base form, combined with binder and lubricant excipients. Implantable drug delivery devices including the tablets are also provided, e.g., one or more of the drug tablets may be contained in a biocompatible housing. The drug tablets may be substantially cylindrical with flat end faces, and the device may have from 10 to 100 drug tablets aligned in the housing with the flat end faces of adjacent tablets abutting one another.Type: ApplicationFiled: June 28, 2010Publication date: December 30, 2010Applicant: TARIS Biomedical, Inc.Inventors: Karen Danielle Daniel, Burleigh M. Hutchins, III, Cheryl Larrivee-Elkins, Heejin Lee
-
Publication number: 20100330150Abstract: The present invention is directed to pharmaceutical compositions comprising a plurality of taste-masked high-dose/low-dose drug-containing microparticles, dosage forms comprising such pharmaceutical compositions (such as an orally disintegrating tablet), and methods of making the pharmaceutical compositions and dosage forms of the present invention. Dosage forms comprising the pharmaceutical compositions of the present invention are improved homogeneous blends of high-dose and low-dose drugs which provide for more convenient and palatable administration of drug combinations, for example for treating pain, hyperglycemia, cardiovascular disease, and allergies.Type: ApplicationFiled: May 3, 2010Publication date: December 30, 2010Inventors: Gopi Venkatesh, Michael Gosselin, James Clevenger, Jin-Wang Lai
-
Publication number: 20100330151Abstract: The present invention is directed to a method of treating or maintaining protection from episodic gastrointestinal disturbances, by providing a composition comprising a probiotic microorganism and chocolate wherein said probiotic microorganism is selected from the group consisting of Bifidobacterium and mixtures thereof; and administering said composition to a mammal.Type: ApplicationFiled: June 8, 2010Publication date: December 30, 2010Inventors: Mary Elaine Freeland, Vincent York-Leung Wong
-
Publication number: 20100330152Abstract: This invention relates to compositions and methods for inhibition of abnormal proliferation of cells or angiogenesis. More particularly this invention provides VEGF antisense oligonucleotides capable of inhibiting proliferation of cancer cells or angiogenesis or combinations thereof. also provided are screening and prognostic assays, as well kits comprising the VEGF antisense oligonucleotides.Type: ApplicationFiled: October 5, 2009Publication date: December 30, 2010Applicant: VasGene Therapeutics, Inc.Inventors: Parkash Gill, Rizwan Masood, Sudhir Agrawal
-
Publication number: 20100330153Abstract: The present invention provides a production method for obtaining a biologically ingestible material having an intended diameter with low energy as compared with conventional methods, the method includes mixing a fluid to be processed in a dispersed phase containing a pharmacologically active substance and a fluid to be processed in a continuous phase including at least a disperse solvent, while each of the fluids are retained in an independent state, in a thin film fluid formed between two processing surfaces arranged to be opposite to each other to be able to approach to and separate from each other, at least one of which rotates relative to the other, through independent pathways corresponding to the respective phases, whereby the components contained in the fluid to be processed in a dispersed phase are formed into microparticles having a desired diameter.Type: ApplicationFiled: September 10, 2008Publication date: December 30, 2010Applicant: M. Technique Co., Ltd.Inventor: Masakazu Enomura
-
Publication number: 20100330154Abstract: An amphoteric liposome comprising neutral lipids wherein said neutral lipids are selected from the group comprising cholesterol or mixtures of cholesterol and at least one neutral or zwitterionic lipid and wherein K (neutral) of said mixtures is 0.3 or less. Said amphoteric liposome may encapsulate an active agent, such as nucleic acid therapeutics. Also disclosed are pharmaceutical compositions comprising said amphoteric liposomes as a carrier for the delivery or targeted delivery of active agents or ingredients.Type: ApplicationFiled: October 12, 2008Publication date: December 30, 2010Inventors: Steffen Panzner, Silke Lutz, Evgenios Siepi, Claudia Muller, Ute Vinzens
-
Publication number: 20100330155Abstract: The present invention relates to chemically modified, linked double-stranded (ds)RNA compositions comprising two or more double-stranded (ds) oligoribonucleotides linked by at least one linking moiety and methods of formulating and delivering such compositions to modulate gene expression through target-specific RNA co-interference (RNAco-i). The compositions of the invention may optionally comprise a conjugation or a complex with one or more small molecule drugs, protein therapeutics, or other dsRNA molecules. The present invention is directed at the methods of production for, methods of use of, and therapeutic utilities for RNAi co-interference therapy utilizing the compositions of the invention.Type: ApplicationFiled: January 19, 2010Publication date: December 30, 2010Applicant: FLAGSHIP VENTURESInventors: David Arthur Berry, Noubar Boghos Afeyan, Chris Varma
-
Publication number: 20100330156Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.Type: ApplicationFiled: March 22, 2010Publication date: December 30, 2010Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Jun O. LIU, Yunzhao REN, Fan PAN, Curtis R. CHONG, Reinhold PENNER, Jonathan R. BEHR
-
Publication number: 20100330157Abstract: The disclosure relates to a biomaterial that comprises an aqueous phase, polymer network, a second polymer included in said disclosure invention more particularly relates to a biomaterial including an aqueous phase and a first polymer network made of a first proteic or saccharidic polymer or a mixture of first proteic and saccharidic polymers, wherein the first polymer network and the aqueous phase define a first gel (A), the biomaterial including: a second proteic or saccharidic polymer or a mixture of the second proteic and saccharidic polymers, either in solution in the aqueous phase of the gel (A) or in the form of a gel (B), and a first enzyme for degrading said second polymer or second polymer network. The disclosure also relates to a method for making biomaterials, and to the uses of the biomaterial particularly for releasing active substances, and to a device for the controlled release of active substances that include the biomaterial.Type: ApplicationFiled: November 13, 2008Publication date: December 30, 2010Applicant: MA.I.A WoundcareInventors: Véronique Laretta-Garde, Julien Picard, Marie Cécile Klak, Sébastien Perrin, Sébastien Giraudier
-
Publication number: 20100330158Abstract: The present invention provides a composition and prodrug for targeted drug delivery to the central nervous system of a patient. The inventive composition and prodrug include a pharmaceutically acceptable active agent and at least one protein selected from the group consisting of a fimbrial adhesin protein, a membrane protein, and combinations thereof. The inventive compositions and prodrugs of the present invention selectively target the blood-brain barrier and deliver hydrophilic and lipophilic active agents of varying sizes to the central nervous system.Type: ApplicationFiled: March 26, 2010Publication date: December 30, 2010Applicant: InnoPharma, LLCInventors: Vishal Soni, Kanaiyalal R. Patel, Dasaradhi Lakkaraju, Navneet Puri
-
Publication number: 20100330159Abstract: A stabilizer-free system for transporting active substances in a biological system of one or more active substances and magnetic particles, which is characterized in that the particles are provided with active substance(s) on at least part of their surface, is claimed. Modification of the magnetic particles is not absolutely required in this system. It can be incorporated both into aqueous and oily suspensions and into microemulsions, oil-in-water emulsions, water-in-oil emulsions and also water-in-oil-in-water emulsions.Type: ApplicationFiled: June 1, 2010Publication date: December 30, 2010Applicant: EUCRO EUROPEAN CONTRACT RESEARCH GMBH & CO. KGInventors: Helmut Blum, Marcel Roth, Wolfgang Greb
-
Publication number: 20100330160Abstract: The invention especially relates to multivalent vaccine compositions that can treat or prevent at least 60, preferably 75% of infections caused by Neisseria meningitidis especially of serogroup B. To this end, the invention in particular provides a lipooligosaccharide (LOS) of N. meningitidis in particular constituted by a lipid A, an inner core, an ? chain of L6 or L8 type, in which the heptose II residue of the inner core bears in position O-3 and in position O-6 or O-7 a phosphoethanolamine (PEA) substituent, and also to the construction of the strain of N. meningitidis that is capable of expressing such an LOS. The invention also relates to a strain of N. meningitidis of serogroup A that bears a lipooligosaccharide (LOS) in particular constituted by a lipid A, an inner core, an ? chain of L6 type, in which the heptose II residue of the inner core bears in position O-3 a phosphoethanolamine (PEA) substituent and does not bear a PEA substituent in positions O-6 and O-7.Type: ApplicationFiled: May 14, 2010Publication date: December 30, 2010Applicant: Sanofi PasteurInventors: Noëlle Mistretta, Monique Moreau, Geneviève Renauld-Mongenie, Bachra Rokbi
-
Publication number: 20100330161Abstract: Orally active vitamin B12-tetanus toxoid (TT) conjugates are described. Attachment of TT to vitamin B12 provides for uptake of the conjugate from the digestive tract, and allows for delivery of the immunologically active TT to the blood. Pharmaceutical compositions and methods of disease prevention employing the orally active Vitamin B12-TT conjugate of the invention are also described.Type: ApplicationFiled: June 29, 2010Publication date: December 30, 2010Applicant: SYRACUSE UNIVERSITY TECHNOLOGY TRANSFER AND INDUSTRIAL DEVELOPMENT OFFICEInventors: Robert Patrick Doyle, Anthony Vortherms
-
Publication number: 20100330162Abstract: This invention provides methods and compositions to preserve bioactive materials, such as viruses, bacteria, cells, or liposomes, in freeze dried particles suitable for pulmonary administration. Methods provide spray freeze drying of formulations to form stable freeze dried particles.Type: ApplicationFiled: September 1, 2010Publication date: December 30, 2010Applicants: Medlmmune, LLC, The Regents of the University of Colorado, a body corporationInventors: Vu Truong-Le, Binh V. Pham, John F. Carpenter, Robert Seid, Theodore W. Randolph
-
Publication number: 20100330163Abstract: Methods and compositions are provided for increasing responsiveness to therapeutic metalloproteases including increasing and/or maximizing responsiveness and preventing botulinum and tetanus toxin resistance due to a functional deficiency of zinc. Also provided are methods for zinc replacement or supplement in lacking individuals comprising the administration of a zinc supplement for a loading period and/or administration of a phytase supplement together with the zinc supplement. Also provided are methods for standardization of botulinum toxin potency assays that provide for greater certainty and margins of safety in the use of products from different manufacturers.Type: ApplicationFiled: June 23, 2010Publication date: December 30, 2010Inventor: Charles N.S. Soparkar
-
Publication number: 20100330164Abstract: A method and preparation for the stimulation of tear secretion in a subject in need of such treatment is disclosed. The method comprises administering to the ocular surfaces of the subject a purinergic receptor agonist such as uridine 5?-triphosphate (UTP), dinucleotides, cytidine 5?-triphosphate (CTP), adenosine 5?-triphosphate (ATP), or their therapeutically useful analogs and derivatives, in an amount effective to stimulate tear fluid secretion and enhance drainage of the lacrimal system. Pharmaceutical formulations and methods of making the same are also disclosed. Methods of administering the same would include: topical administration via a liquid, gel, cream, or as part of a contact lens or selective release membrane; or systemic administration via nasal drops or spray, inhalation by nebulizer or other device, oral form (liquid or pill), injectable, intra-operative instillation or suppository form.Type: ApplicationFiled: June 28, 2010Publication date: December 30, 2010Inventors: Benjamin R. Yerxa, Karla M. Jacobus, William Pendergast, Janet L. Rideout
-
Publication number: 20100330165Abstract: The use of chemotherapeutic agents for the preparation of a medicament for the topical and/or local treatment of diseases caused by bacteria and/or for prophylaxis in humans or animals.Type: ApplicationFiled: August 18, 2010Publication date: December 30, 2010Applicant: Bayer Innovation GmbHInventors: HANS-HERRMANN SCHULZ, Günther Schlimbach